Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform
Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise biomedicine. Global burden of heart failure will soon reach USD $90bn, while unexpected cardiotoxicity underlies 28% of drug withdrawals. Advances in hPSC isolation, Cas9/CRISPR genome engineering and hPSC-CM differenti...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Elsevier
2016
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/37771/ |
| _version_ | 1848795530171252736 |
|---|---|
| author | Denning, Chris Borgdorff, Viola Crutchley, James Firth, Karl S.A. George, Vinoj Kalra, Spandan Kondrashov, Alexander Hoang, Minh Duc Mosqueira, Diogo Patel, Asha Prodanov, Ljupcho Rajamohan, Divya Skarnes, William C. Smith, James G.W. Young, Lorraine E. |
| author_facet | Denning, Chris Borgdorff, Viola Crutchley, James Firth, Karl S.A. George, Vinoj Kalra, Spandan Kondrashov, Alexander Hoang, Minh Duc Mosqueira, Diogo Patel, Asha Prodanov, Ljupcho Rajamohan, Divya Skarnes, William C. Smith, James G.W. Young, Lorraine E. |
| author_sort | Denning, Chris |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise biomedicine. Global burden of heart failure will soon reach USD $90bn, while unexpected cardiotoxicity underlies 28% of drug withdrawals. Advances in hPSC isolation, Cas9/CRISPR genome engineering and hPSC-CM differentiation have improved patient care, progressed drugs to clinic and opened a new era in safety pharmacology. Nevertheless, predictive cardiotoxicity using hPSC-CMs contrasts from failure to almost total success. Since this likely relates to cell immaturity, efforts are underway to use biochemical and biophysical cues to improve many of the ~ 30 structural and functional properties of hPSC-CMs towards those seen in adult CMs. Other developments needed for widespread hPSC-CM utility include subtype specification, cost reduction of large scale differentiation and elimination of the phenotyping bottleneck. This review will consider these factors in the evolution of hPSC-CM technologies, as well as their integration into high content industrial platforms that assess structure, mitochondrial function, electrophysiology, calcium transients and contractility. This article is part of a Special Issue entitled: Cardiomyocyte Biology: Integration of Developmental and Environmental Cues in the Heart edited by Marcus Schaub and Hughes Abriel. |
| first_indexed | 2025-11-14T19:33:33Z |
| format | Article |
| id | nottingham-37771 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T19:33:33Z |
| publishDate | 2016 |
| publisher | Elsevier |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-377712020-05-04T17:58:50Z https://eprints.nottingham.ac.uk/37771/ Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform Denning, Chris Borgdorff, Viola Crutchley, James Firth, Karl S.A. George, Vinoj Kalra, Spandan Kondrashov, Alexander Hoang, Minh Duc Mosqueira, Diogo Patel, Asha Prodanov, Ljupcho Rajamohan, Divya Skarnes, William C. Smith, James G.W. Young, Lorraine E. Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise biomedicine. Global burden of heart failure will soon reach USD $90bn, while unexpected cardiotoxicity underlies 28% of drug withdrawals. Advances in hPSC isolation, Cas9/CRISPR genome engineering and hPSC-CM differentiation have improved patient care, progressed drugs to clinic and opened a new era in safety pharmacology. Nevertheless, predictive cardiotoxicity using hPSC-CMs contrasts from failure to almost total success. Since this likely relates to cell immaturity, efforts are underway to use biochemical and biophysical cues to improve many of the ~ 30 structural and functional properties of hPSC-CMs towards those seen in adult CMs. Other developments needed for widespread hPSC-CM utility include subtype specification, cost reduction of large scale differentiation and elimination of the phenotyping bottleneck. This review will consider these factors in the evolution of hPSC-CM technologies, as well as their integration into high content industrial platforms that assess structure, mitochondrial function, electrophysiology, calcium transients and contractility. This article is part of a Special Issue entitled: Cardiomyocyte Biology: Integration of Developmental and Environmental Cues in the Heart edited by Marcus Schaub and Hughes Abriel. Elsevier 2016-07-31 Article PeerReviewed Denning, Chris, Borgdorff, Viola, Crutchley, James, Firth, Karl S.A., George, Vinoj, Kalra, Spandan, Kondrashov, Alexander, Hoang, Minh Duc, Mosqueira, Diogo, Patel, Asha, Prodanov, Ljupcho, Rajamohan, Divya, Skarnes, William C., Smith, James G.W. and Young, Lorraine E. (2016) Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform. BBA - Biochimica et Biophysica Acta, 1863 (7). pp. 1728-1748. ISSN 0006-3002 Human embryonic stem cells; human induced pluripotent stem cells; cas9/CRISPR genome editing; cardiomyocytes; drug screening; disease modelling; maturation factors; muscular thin films; engineered heart tissue; automated scalability; high content platforms; calcium imaging; electrophysiology; mitochondria; contractility http://www.sciencedirect.com/science/article/pii/S0167488915003675 doi:10.1016/j.bbamcr.2015.10.014 doi:10.1016/j.bbamcr.2015.10.014 |
| spellingShingle | Human embryonic stem cells; human induced pluripotent stem cells; cas9/CRISPR genome editing; cardiomyocytes; drug screening; disease modelling; maturation factors; muscular thin films; engineered heart tissue; automated scalability; high content platforms; calcium imaging; electrophysiology; mitochondria; contractility Denning, Chris Borgdorff, Viola Crutchley, James Firth, Karl S.A. George, Vinoj Kalra, Spandan Kondrashov, Alexander Hoang, Minh Duc Mosqueira, Diogo Patel, Asha Prodanov, Ljupcho Rajamohan, Divya Skarnes, William C. Smith, James G.W. Young, Lorraine E. Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform |
| title | Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform |
| title_full | Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform |
| title_fullStr | Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform |
| title_full_unstemmed | Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform |
| title_short | Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform |
| title_sort | cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform |
| topic | Human embryonic stem cells; human induced pluripotent stem cells; cas9/CRISPR genome editing; cardiomyocytes; drug screening; disease modelling; maturation factors; muscular thin films; engineered heart tissue; automated scalability; high content platforms; calcium imaging; electrophysiology; mitochondria; contractility |
| url | https://eprints.nottingham.ac.uk/37771/ https://eprints.nottingham.ac.uk/37771/ https://eprints.nottingham.ac.uk/37771/ |